SPONSORED CONTENT
Attention 340B Covered Entities: The 340B drug pricing program is entering an exciting phase of evolution. The SUSTAIN 340B Act and the 340B Patients Act demonstrate a strong commitment to refining the program, ensuring it serves patients effectively while maintaining accountability. This active legislative engagement, alongside legal discussions and state-level initiatives, signals a healthy process of improvement. Covered entities (CEs) now have a unique opportunity to collaborate with policymakers and shape the 340B program to best serve those in need.
This webinar will help you understand the potential changes, and equip you to advocate for your interests. Here’s what we’ll cover:
- Manufacturer Restrictions: Analyze recent limitations and their potential impact on CEs.
- Understanding Key Legislation: Compare and contrast the SUSTAIN 340B Act and the 340B Patients Act.
- Examining the Arkansas Victory: Learn how this legal win could affect challenges to manufacturer restrictions.
- Tracking State-Level Legislation: Discover which states support or
